Questcor®

For assistance with any problem or issue, please contact customer service at 1.800.411.3065 (M-F from 8:00 a.m. to 4:00 p.m. Pacific Standard Time.)

In the event of an emergency, please contact us 24 hours a day, 7 days a week at 1.800.411.3065

Working for a small company like Questcor allows you the opportunity to express and implement your own unique ideas. The company encourages professional growth without boundaries.

-Christine T.
Acthar Specialist

Questcor's working environment has allowed me to be successful by offering an excellent management team, realistic attainable goals, and a competitive compensation plan.

-Doug D.
Regional Manager

Hard work, teamwork, and a can-do spirit personify the people and the culture at Questcor.

-Todd B.
Acthar Specialist

Working at Questcor has been a rewarding growth opportunity both personally and professionally. Over the years and through many changes in the company, it has been a great experience to work with so many talented people who are focused on improving the lives of patients suffering from CNS and inflammatory disorders.

-Heather B.
Market Research

This is a place where your ideas and opinions not only matter, but are encouraged. Truly unique, like no other company you will work for, a company with a very bright future.

-Matthew D.
Regional Manager

For me working at Questcor has been great. The company culture is excellent; I have a diversity of responsibilities, and most importantly I have very good work/life balance.

-Temi O.
Finance and Accounting

Company History

Questcor Pharmaceuticals Inc. was formed on November 17, 1999 when Cypros Pharmaceutical Corporation and RiboGene Inc. merged to become one integrated company. See below for some key dates, milestones, and accomplishments from our history.

Company Timeline
1999	Formation of Questcor through merger of RiboGene Inc. and Cypros Pharmaceutical Corporation
2001	Questcor acquires Acthar^® Gel from Aventis
2005	Questcor divests Nascobal^®, Glofil^® and Ethamolin^® to QOL Medical
2007	Questcor initiates new orphan strategy for Acthar Questcor dramatically expands funding for patient assistance programs First profitable year in Questcor's history
2008	Questcor moves to NASDAQ Questcor initiates effort to evaluate Acthar in nephrotic syndrome Questcor submits sNDA for IS indication to FDA Questcor records second consecutive profitable year